Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pravachol OTC Deal Reached Between Bayer, Bristol

This article was originally published in The Tan Sheet

Executive Summary

Bayer is following through on its aim to become the preeminent switch player through a deal with Bristol-Myers Squibb for OTC Pravachol in the U.S

You may also be interested in...



Bayer Pravachol switch program still alive

Bayer HealthCare is "working with the FDA" on its planned Rx-to-OTC switch of Bristol-Myers Squibb's cholesterol drug, Pravachol, Gary Balkema, the firm's Consumer Care Division president, says June 19. During Bayer's investor conference in Leverkusen, Germany, Balkema said gaining FDA approval for low-dose Pravachol is the division's top switch priority. "Companies that have the ability to introduce switches see some significant growth opportunities and we plan to be one of those companies," he said, adding Bayer will "explore additional switch opportunity projects." Bayer acquired U.S. marketing rights for a switch of the statin in 2004 (1"The Tan Sheet" Dec. 13, 2004, p. 5). An advisory panel review would be the second time around for pravastatin, which went before a joint panel in 2000 and failed to gain approval from the agency, as did Merck's Mevacor (lovastatin). The agency's Nonprescription Drugs and Endocrinologic & Metabolic Drugs advisory committees again voted against J&J and Merck's switch proposal for Mevacor in 2005 (2"The Tan Sheet" Jan. 17, 2005, p. 3). Following the vote, Merck has worked with FDA on labeling to be tested for an OTC Mevacor and on testing methodologies (3"The Tan Sheet" March 20, 2006, p. 4)...

Bayer Pravachol switch program still alive

Bayer HealthCare is "working with the FDA" on its planned Rx-to-OTC switch of Bristol-Myers Squibb's cholesterol drug, Pravachol, Gary Balkema, the firm's Consumer Care Division president, says June 19. During Bayer's investor conference in Leverkusen, Germany, Balkema said gaining FDA approval for low-dose Pravachol is the division's top switch priority. "Companies that have the ability to introduce switches see some significant growth opportunities and we plan to be one of those companies," he said, adding Bayer will "explore additional switch opportunity projects." Bayer acquired U.S. marketing rights for a switch of the statin in 2004 (1"The Tan Sheet" Dec. 13, 2004, p. 5). An advisory panel review would be the second time around for pravastatin, which went before a joint panel in 2000 and failed to gain approval from the agency, as did Merck's Mevacor (lovastatin). The agency's Nonprescription Drugs and Endocrinologic & Metabolic Drugs advisory committees again voted against J&J and Merck's switch proposal for Mevacor in 2005 (2"The Tan Sheet" Jan. 17, 2005, p. 3). Following the vote, Merck has worked with FDA on labeling to be tested for an OTC Mevacor and on testing methodologies (3"The Tan Sheet" March 20, 2006, p. 4)...

Bayer Pravachol switch program still alive

Bayer HealthCare is "working with the FDA" on its planned Rx-to-OTC switch of Bristol-Myers Squibb's cholesterol drug, Pravachol, Gary Balkema, the firm's Consumer Care Division president, says June 19. During Bayer's investor conference in Leverkusen, Germany, Balkema said gaining FDA approval for low-dose Pravachol is the division's top switch priority. "Companies that have the ability to introduce switches see some significant growth opportunities and we plan to be one of those companies," he said, adding Bayer will "explore additional switch opportunity projects." Bayer acquired U.S. marketing rights for a switch of the statin in 2004 (1"The Tan Sheet" Dec. 13, 2004, p. 5). An advisory panel review would be the second time around for pravastatin, which went before a joint panel in 2000 and failed to gain approval from the agency, as did Merck's Mevacor (lovastatin). The agency's Nonprescription Drugs and Endocrinologic & Metabolic Drugs advisory committees again voted against J&J and Merck's switch proposal for Mevacor in 2005 (2"The Tan Sheet" Jan. 17, 2005, p. 3). Following the vote, Merck has worked with FDA on labeling to be tested for an OTC Mevacor and on testing methodologies (3"The Tan Sheet" March 20, 2006, p. 4)...

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS097626

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel